# Daniel P. Petrylak

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-p-petrylak/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,455 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 88 |
| i10-index | 344 |
| OpenAlex ID | https://openalex.org/A5050042851 |
| ORCID iD | https://orcid.org/0000-0001-6165-5797 |
| Works | 830 |

## Researcher papers

- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer](https://scholariq.org/papers/docetaxel-and-estramustine-compared-with-mitoxantrone-and-prednisone-for/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group](https://scholariq.org/papers/eligibility-and-response-guidelines-for-phase-ii-clinical-trials-in-androgen/)
- [TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors](https://scholariq.org/papers/trophy-u-01-a-phase-ii-open-label-study-of-sacituzumab-govitecan-in-patients/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells](https://scholariq.org/papers/suppression-of-acquired-docetaxel-resistance-in-prostate-cancer-through/)
- [Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer](https://scholariq.org/papers/phase-i-trial-of-docetaxel-with-estramustine-in-androgen-independent-prostate/)
- [Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16](https://scholariq.org/papers/evaluation-of-prostate-specific-antigen-declines-for-surrogacy-in-patients/)
- [Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial](https://scholariq.org/papers/ramucirumab-plus-pembrolizumab-in-patients-with-previously-treated-advanced-non/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.